Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab

Trial Profile

Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SwapTwo
  • Most Recent Events

    • 29 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.
    • 29 Sep 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2018.
    • 08 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top